within Pharmacolibrary.Drugs.ATC.D;

model D01AC02_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.115,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.00032,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Miconazole is an imidazole antifungal medication primarily used to treat superficial fungal infections, such as athlete's foot, ringworm, and candidiasis (including oral and vaginal candidiasis). It functions by inhibiting ergosterol synthesis, disrupting fungal cell membrane integrity. Miconazole is approved and widely used in topical, oral, and occasionally intravenous formulations for the treatment of fungal infections in various countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in hospitalized adults following intravenous infusion.</p><h4>References</h4><ol><li><p>Bodey, GP (1992). Azole antifungal agents. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 14 Suppl 1 S161–S169. DOI:<a href=&quot;https://doi.org/10.1093/clinids/14.supplement_1.s161&quot;>10.1093/clinids/14.supplement_1.s161</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1314105/&quot;>https://pubmed.ncbi.nlm.nih.gov/1314105</a></p></li><li><p>Piel, G, et al., &amp; Delattre, L (1999). Comparison of the IV pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar solution. <i>International journal of pharmaceutics</i> 180(1) 41–45. DOI:<a href=&quot;https://doi.org/10.1016/s0378-5173(98)00403-7&quot;>10.1016/s0378-5173(98)00403-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10089290/&quot;>https://pubmed.ncbi.nlm.nih.gov/10089290</a></p></li><li><p>Mikamo, H, et al., &amp; Tamaya, T (1997). Pharmacokinetics of miconazole in serum and exudate of pelvic retroperitoneal space after radical hysterectomy and pelvic lymphadenectomy. <i>International journal of antimicrobial agents</i> 9(3) 207–211. DOI:<a href=&quot;https://doi.org/10.1016/s0924-8579(97)00050-2&quot;>10.1016/s0924-8579(97)00050-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9552718/&quot;>https://pubmed.ncbi.nlm.nih.gov/9552718</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D01AC02_1;
